Most Read Articles
Hannah Wong, 30 Sep 2019

Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.

Tristan Manalac, 19 Nov 2019
Dapagliflozin is able to delay renal disease progression among patients with type 2 diabetes, even in those with normal kidney function, according to a study presented at the recently concluded Kidney Week 2019 of the American Society of Nephrology (ASN 2019).
07 Oct 2019
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.
09 Oct 2019
In diabetic adults, the presentation of renal disease is heterogenous and involves different mechanisms of action, a new Japan study has found.

Diabetes solutions provider, retail pharmacy partner for diabetes management subscription plan

Rachel Soon
Medical Writer
15 Nov 2019
Lee Yin Chen, director of Brand and Trade Marketing, Alpro Pharmacy, and Maximilian Lim, managing director, Ascensia Diabetes Care Malaysia at the launch of sugO365, a first-in-kind diabetes management subscription programme.

In conjunction with World Diabetes Day on 14 November, diabetes solutions provider Ascensia Diabetes Care and local retail pharmacy chain Alpro Pharmacy have launched a first-in-kind diabetes management programme in Malaysia.

Conceptualized by a team of local healthcare professionals, the sugO365 programme aims to provide affordable and accessible assistance through digital solutions for patients with diabetes who seek more effective management of their condition.

“Self-monitoring blood glucose (SMBG) is undeniably an important aspect for those living with diabetes,” said Maximillian Lim, managing director, Ascensia Diabetes Care Malaysia. “As the world’s leading diabetes care solutions provider, we are committed to simplifying the lives of people with diabetes, empowering them to take charge of their health.”

Under any of four sugO365 subscription plans (sugOTrial, sugOVIP, sugOCOMBO, and sugOMAX), patients will receive a wireless-enabled glucometer which can connect to a corresponding smartphone app via Bluetooth®. The app will collect, store, and analyze the patient’s blood glucose readings in real-time, which will assist them in understanding how their daily activities affect their blood glucose levels and subsequent disease management.

Subscribers will also be entitled to personalized care from Alpro Pharmacy’s certified pharmacists, nutritionists, and dietitians through live chat and face-to-face consultation. Webinars and diabetes health tips will also be accessible through the plan.

According to Lim, a recent survey conducted by Ascensia found that patients living with diabetes are discouraged from performing appropriate SMBG due to financial costs. Over 50% of respondents with diabetes believed that doctors were primarily responsible for diabetes management, rather than patients themselves.

“We believe that the subscription plan will address the issues of affordability and access to timely and accurate information,” said Lim, “We hope to empower people with diabetes to take charge of their condition.”

According to Lee Yin Chen, Alpro Pharmacy’s branding, promotion and trade marketing director, the American Diabetes Association has estimated medical costs of approximately RM71,000 (US$16,750) per year for a person living with diabetes; of that amount, RM41,000 (US$9,601) is incurred by diabetes treatment alone.

“With sugO365, we can help to relieve the [financial] burden on patients facing high diabetes expenses. Most importantly, they will get access to accurate information at their fingertips,” said Lee. “Moving forward, both Ascensia and Alpro will continue to bring about more features to this subscription plan … Our ultimate goal is to encourage Malaysians to take charge of their own lives and encourage their loved ones to do the same.”

SugOVIP, the most comprehensive plan of the four, is priced at RM360 and upwards for the year and is available to all Alpro Pharmacy members. In conjunction with the launch of sugO365, Alpro Pharmacy customers who have purchased a corresponding insurance package during the campaign period will be entitled to a complimentary 1-year sugOVIP subscription.

Further information on the sugO365 programme is available at www.sugo365.com.my or Alpro Pharmacy outlets.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Hannah Wong, 30 Sep 2019

Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.

Tristan Manalac, 19 Nov 2019
Dapagliflozin is able to delay renal disease progression among patients with type 2 diabetes, even in those with normal kidney function, according to a study presented at the recently concluded Kidney Week 2019 of the American Society of Nephrology (ASN 2019).
07 Oct 2019
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.
09 Oct 2019
In diabetic adults, the presentation of renal disease is heterogenous and involves different mechanisms of action, a new Japan study has found.